Please login to the form below

Not currently logged in
Email:
Password:

Roche sues Dr Reddy's over Boniva for osteoporosis

Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of osteoporosis drug Boniva

Swiss-based pharmaceutical company Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of Roche's osteoporosis drug Boniva (ibandronate).

The complaint was filed on 20 September in a New Jersey court. Roche says that Boniva is covered by patents running from 2012 to 2023.

In a statement, Roche said: "This action arises because of Dr Reddy's efforts to gain approval from the FDA to market a generic copy of Roche's Boniva once-monthly drug product prior to the expiration of Roche's patent rights covering it."

Earlier in September, Roche initiated legal action against Israel-headquartered generics giant Teva Pharmaceutical's move to enter the US market with a Boniva copy.

Boniva, which is sold under the name of Bonviva in the EU, racked up sales of CHF 488m in FY06.

25th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics